<?xml version="1.0" encoding="UTF-8"?>
<ref id="B161-molecules-25-04036">
 <label>161.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>McGuire</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Robson</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Cuba≈Ça</surname>
    <given-names>W.J.</given-names>
   </name>
   <name>
    <surname>Vasile</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Morrison</surname>
    <given-names>P.D.</given-names>
   </name>
   <name>
    <surname>Barron</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Taylor</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Wright</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial</article-title>
  <source>Am. J. Psychiatry</source>
  <year>2018</year>
  <volume>175</volume>
  <fpage>225</fpage>
  <lpage>231</lpage>
  <pub-id pub-id-type="doi">10.1176/appi.ajp.2017.17030325</pub-id>
  <pub-id pub-id-type="pmid">29241357</pub-id>
 </element-citation>
</ref>
